Table of Contents 3
List of Tables 6
List of Figures 6
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16
Venture Financing 17
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Wilson Therapeutics Raises US$40 Million In Series B Financing 19
Private Equity 21
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 21
Partnerships 22
Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22
Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24
X-Chem Enters into Discovery Agreement with Alexion Pharma 25
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28
Licensing Agreements 29
Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34
Equity Offering 35
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35
Wilson Therapeutics Raises USD48 Million in IPO 37
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 42
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 44
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 46
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 47
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 49
Asset Transactions 51
BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51
Acquisition 52
Alexion Pharma Acquires Syntimmune 52
Alexion Acquires Wilson Therapeutics for USD852 Million 53
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57
Alexion Pharma Completes Acquisition Of Enobia Pharma 58
Alexion Pharmaceuticals Inc - Key Competitors 60
Alexion Pharmaceuticals Inc - Key Employees 61
Alexion Pharmaceuticals Inc - Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Recent Developments 65
Strategy And Business Planning 65
Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 65
Financial Announcements 67
Oct 24, 2018: Alexion reports third quarter 2018 results 67
Jul 26, 2018: Alexion Reports Second Quarter 2018 Results 69
Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study 71
Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018 73
Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 75
Apr 27, 2017: Alexion Reports First Quarter 2017 Results 76
Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 77
Corporate Communications 79
Feb 05, 2018: Alexion Pharmaceuticals Names Judith A. Reinsdorf As Board Director 79
Jan 22, 2018: Alexion Pharmaceuticals Names Deborah Dunsire As Board Director 80
Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 81
Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 82
Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 83
Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 84
May 23, 2017: Alexion Announces Executive Leadership Changes 86
Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 88
Mar 24, 2017: Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG 89
Mar 02, 2017: Leonard Bell, M.D., Alexion’s Founder, Announces Plans to Retire as Chairman and Board Member 90
Product News 92
12/11/2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting 92
11/01/2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting 94
01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 95
Product Approvals 96
Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US 96
Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU) 98
Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S. 99
Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease 101
Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS 102
Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 103
Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 104
Clinical Trials 105
Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA) 105
Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology 106
Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting 108
Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting 110
Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 112
Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease 114
Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease 115
Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting 117
Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology 119
Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting 120
Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting 122
Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting 123
Apr 24, 2017: Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting 125
Apr 05, 2017: Final Phase 2 Results For WTX-101 Accepted As A Late-Breaker Presentation At EASL Annual Meeting 127
Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 128
Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 129
Other Significant Developments 130
Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 130
Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 131
Appendix 133
Methodology 133
About GlobalData 133
Contact Us 133
Disclaimer 133

List of Tables
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Wilson Therapeutics Raises US$40 Million In Series B Financing 19
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 21
Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22
Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24
X-Chem Enters into Discovery Agreement with Alexion Pharma 25
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28
Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35
Wilson Therapeutics Raises USD48 Million in IPO 37
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 42
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 44
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 46
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 47
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 49
BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51
Alexion Pharma Acquires Syntimmune 52
Alexion Acquires Wilson Therapeutics for USD852 Million 53
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57
Alexion Pharma Completes Acquisition Of Enobia Pharma 58
Alexion Pharmaceuticals Inc, Key Competitors 60
Alexion Pharmaceuticals Inc, Key Employees 61
Alexion Pharmaceuticals Inc, Subsidiaries 62

List of Figures
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13